The US FDA is moving to fast-track the review of certain psychedelic drugs, with some reports specifying that three drug studies are involved. The move appears to be related to an order from Trump, although the details of the order and its motivation are not clear. The drugs in question are being considered for their potential use in treating mental health conditions, with psilocybin and methylone mentioned as specific examples in some reports.